Fabian Rosel
Psychiatric/Mental Health · Steubenville, OHNPI 1174925838
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 29.2% of the total. 2025 is the largest year on record at $894, more than ten times the $74 reported in 2021.
Across 125 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$652
- Supernus Pharmaceuticals, Inc.$241
- Ironshore Pharmaceuticals Inc.$213
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$202
- Corium, LLC$180
- Otsuka America Pharmaceutical, Inc.$133
- plus $611 from 9 others
What the payments were for
- Food & beverage$2,17598%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $652 |
| Supernus Pharmaceuticals, Inc. | 13 | $241 |
| Ironshore Pharmaceuticals Inc. | 11 | $213 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $202 |
| Corium, LLC | 9 | $180 |
| Otsuka America Pharmaceutical, Inc. | 6 | $133 |
| Axsome Therapeutics, Inc. | 7 | $129 |
| Teva Pharmaceuticals USA, Inc. | 5 | $106 |
| Lundbeck LLC | 4 | $90 |
| Collegium Pharmaceutical, Inc. | 4 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Alkermes, Inc. | 3 | $55 |
| Tris Pharma Inc | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 1 | $38 |
| Merck | 1 | $13 |
How this compares
$2,230 in reported general payments places this provider in the 75th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 20 | $6,374 |
| Quetiapine Fumarate | 24 | $798 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $354 |
| Hydroxyzine Pamoate | 12 | $328 |
| Levothyroxine Sodium | 12 | $164 |
| Risperidone | 24 | $154 |
| Buspirone Hcl | 11 | $132 |
| Sertraline Hcl | 13 | $86 |
| Lorazepam | 15 | $52 |
| Fluoxetine Hcl | 15 | $34 |
| Clonazepam | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Steubenville
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
- Danielle MorroneCanfield$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.